

# Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis

**Panagiota I Kontou<sup>1§</sup> PhD, Georgia G Braliou<sup>1§</sup> PhD, Niki L Dimou<sup>2</sup> PhD, Georgios Nikolopoulos<sup>3</sup> PhD, Pantelis G Bagos<sup>1\*</sup> PhD**

**<sup>1</sup>Department of Computer Science and Biomedical Informatics, University of Thessaly,  
Lamia, Greece**

**<sup>2</sup> International Agency for Research on Cancer, Lyon, France**

**<sup>3</sup> Medical School, University of Cyprus, Nicosia, Cyprus**

**<sup>§</sup> These authors contributed equally**

**\*Correspondence to:**

**Prof. Pantelis Bagos,**

**Department of Computer Science and Biomedical Informatics,**

**University of Thessaly,**

**Papasiopoulou 2-4, Lamia 35131, Greece,**

**pbagos@compgen.org, tel. 00302231066914**

# Summary

## Background

With the emergence of SARS-CoV-2 and the associated Coronavirus disease 2019 (COVID-19), there is an imperative need for diagnostic tests that can identify the infection. Although Nucleic Acid Test (NAT) is considered to be the gold standard, serological tests based on antibodies could be very helpful. However, individual studies measuring the accuracy of the various tests are usually underpowered and inconsistent, thus, a comparison of different tests is needed.

## Methods

We performed a systematic review and meta-analysis following the PRISMA guidelines. We conducted the literature search in PubMed, medRxiv and bioRxiv. For the statistical analysis we used the bivariate method for meta-analysis of diagnostic tests pooling sensitivities and specificities. We evaluated IgM and IgG tests based on Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence Enzyme Immunoassays (CLIA), Fluorescence Immunoassays (FIA) and the point-of-care (POC) Lateral Flow Immunoassays (LFIA) that are based on immunochromatography.

## Findings

In total, we identified 38 eligible studies that include data from 7,848 individuals. The analyses showed that tests using the S antigen are more sensitive than N antigen-based tests. IgG tests perform better compared to IgM ones, and show better sensitivity when the samples were taken longer after the onset of symptoms. Moreover, irrespective of the method, a combined IgG/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody type alone. All methods yielded high specificity with some of them (ELISA and LFIA) reaching levels around 99%. ELISA- and CLIA-based methods performed better in terms of sensitivity (90-94%) followed by LFIA and FIA with sensitivities ranging from 80% to 86%.

## Interpretation

ELISA tests could be a safer choice at this stage of the pandemic. POC tests (LFIA), that are more attractive for large seroprevalence studies show high specificity but lower sensitivity and this should be taken into account when designing and performing seroprevalence studies.

## Funding

None

## Introduction

In December 2019, a pneumonia outbreak occurred in Wuhan in China due to a new coronavirus that was later officially named SARS-CoV-2 by the World Health Organization (WHO) <sup>1,2</sup>. The disease rapidly spread worldwide and on February 24, WHO declared COVID-19 (coronavirus disease 2019) a pandemic <sup>3</sup>. SARS-CoV-2 shares pathogenicity features with the human coronaviruses SARS-CoV and MERS-CoV <sup>4</sup> but the incubation period is longer (up to 14 days) <sup>3</sup>. Most patients exhibit mild symptoms and only a few cases progress to severe or critical disease. Risk factors for severe disease include older age <sup>5</sup> and comorbidities such as hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease <sup>6</sup>, whereas a higher incidence in males has also been reported <sup>7</sup>.

The genome of SARS-CoV-2 is predicted to encode 4 structural proteins (including Spike (S), and Nucleocapsid (N)), 8 accessory, and 15 non-structural proteins <sup>8</sup>. The S protein comprises S1, which is responsible for binding to the ACE2 membrane receptor of the host cell <sup>9-12</sup>. The N protein is the structural helical nucleocapsid protein of the virus and is important for transcription and viral replication and packaging <sup>13, 14</sup>. The S and N proteins show high antigenicity <sup>15-17</sup>.

Although rigorous public health measures have been taken globally including mass quarantine, COVID-19 incidence is rising leading to 2,402,980 laboratory-confirmed cases and over 165,641 deaths worldwide by April 20. Due to the ongoing COVID 19 outbreak, there is an urgent global need for diagnostic tests. WHO suggests that detection of SARS-CoV-2 nucleic acid (E gene followed by the RdRp gene) is performed in respiratory samples <sup>18-20</sup>, while the United States Centers for Disease Control (CDC) recommends the nucleocapsid protein targets N1 and N2 <sup>21</sup>. However, the global shortage of diagnostic tests and especially of swabs for collecting respiratory samples, the frequency of false negative results, and the inability of these tests to be performed in a balk and quick manner that is often required at hospital admission, highlight the necessity to develop additional testing methods.

COVID-19 serological tests for IgG and IgM have been developed by many laboratories and companies and can be useful in various ways: a) they can confirm Nucleic Acid Tests (NAT) results or detect infected people who were negative according to NATs <sup>22</sup>, b) they are cheap, quick, and amenable to rapid broad screening at points of care (POC), c) blood/serum samples that are used show reduced heterogeneity compared to respiratory specimens, and d) blood/serum sampling encompasses lower risk for health care workers compared to respiratory sampling where patients are more likely to disperse the virus. Additionally, serological assays can help determine the immune status of individuals <sup>15</sup>, and efforts to estimate herd immunity.

Since all the above serological tests have been developed rapidly and under urgent market demands, they are poorly validated with clinical samples in everyday practice. Within several studies, these tests show divergence in sensitivity and specificity that may deviate from what the manufacturers report. Given the importance of serological tests in combating COVID-19, this systematic review and meta-analysis aims to summarize the available evidence on the performance of all available antibody-tests for SARS-CoV-2.

## Methods

### *Search strategy and selection criteria*

For conducting the systematic review and the meta-analysis we followed the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines <sup>23</sup> and the advises for best practices <sup>24</sup>. We conducted the literature search using PubMed

(<https://www.ncbi.nlm.nih.gov/pubmed/>), medRxiv (<https://medrxiv.org/>) and bioRxiv (<https://www.biorxiv.org/>). The search terms used were: (SARS-CoV-2 OR "Coronavirus disease 2019" OR COVID-19) AND (IgM OR IgG or antibodies OR antibody OR ELISA or "rapid test"). The references of selected articles were also searched. The searches were concluded by April 17, 2020, and four different researchers independently evaluated search results. Disagreements in the initial evaluation were resolved by consensus. We did not impose language criteria and included studies written in English and Chinese. Eligible articles were required to meet the following criteria: a) studies that reported COVID-19 cases confirmed either by NAT such as RT-PCR or sequencing documenting SARS-CoV-2 infection, or by a combination of NAT and clinical findings, and b) results concerning IgM and/or IgG antibodies using a variety of methods. We considered as eligible studies reporting the comparison of COVID-19 cases against non COVID-19 individuals, as well as case series reporting data only from COVID-19 patients.

Data extracted for each study included (if available): first author's last name, percentage of male patients, mean age of COVID-19 patients, mean number of days from onset and percentage of severe or critically-ill COVID-19 patients. In addition, the different methods used for the determination of IgG and IgM were also recorded, along with their details. In order to construct the 2x2 contingency table and obtain estimates for sensitivity and specificity, we obtained the numbers of true positive (TP), false positive (FP), true negative (TN), and false negative (FN). For studies reporting only COVID-19 patients we recorded only TP and FN.

The immunoassay methods used for COVID-19 antibody (Ab) detection in all studies included in the present meta-analysis include Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence Enzyme Immunoassays (CLIA), Fluorescence Immunoassays (FIA), and the point-of-care (POC) lateral flow immunoassays (LFIA) that are based on immunochromatography <sup>25-29</sup>.

All methods were created to detect IgG and/or IgM antibodies (or even total antibodies) <sup>30-32</sup> against S (mainly RBD) and/or N viral proteins of human sera/blood samples. The ELISA method variations include  $\mu$ -chain capture principle for IgM, indirect for IgG and double antigen sandwich for total antibody detection. ELISA gives quantitative data on antibodies by measuring Absorbance values (A450) and cut-off values determined for each test-plate. LFIA is an immunochromatography based assay using colloidal gold conjugated COVID-19 antigens. The test is rapid, performed on test strips of nitrocellulose and gives qualitative results that are judged by optical inspection usually 15 minutes after sample application. In some LFIAs purchased from companies the specific antigen that LFIA was based on was not reported. Due to the fact that most of the companies provide N and S based LFIAs, we assumed that in unspecified cases the LFIAs were N and S based. CLIA is a chemiluminescence based assay, mainly developed by companies giving quantitative results with the use of an analyzer. The analyzer can be batch and random access with the possibility to give results within half an hour at best <sup>33, 34</sup>. Because in most cases CLIA detected both anti-N and anti-S IgG and IgM antibodies, (with only one study detecting anti-N <sup>33, 34</sup>), we assumed N and S based IgG and IgM CLIA in studies without relevant information. With FIA we denote fluorescence immunoassays that can be performed on multitest cover slides <sup>35</sup> or be based on fluorescence immunochromatography (AIE/Quantum dot-based fluorescence immunochromatographic assay, AFIA) <sup>36, 37</sup>. The latter can be rapid but all need analyzers.

### **Data analysis**

We performed a quality assessment of the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool, offered by the Review Manager Software (RevMan 5.2.3). The QUADAS is a quality assessment tool specifically developed for systematic reviews of diagnostic accuracy studies and consists of four key domains: patient

selection, index test, reference standard and flow and timing; each domain is rated as low risk, high risk and unclear risk.

We used the bivariate meta-analytic method modified for the meta-analysis of diagnostic tests<sup>38</sup>. The method has been shown to be equivalent to the so-called hsROC method<sup>39, 40</sup>, and uses logit-transforms of TPR (true positive rate) and FPR (false positive rate) in order to model Sensitivity and Specificity, as well as, to account for the between-studies variability (heterogeneity). Studies that include information only for logit (TPR) are included under the missing at random assumptions in order to maximize the sample and allow for modelling the between-studies variability and correlation. The Begg's rank correlation test<sup>41</sup> and the Egger's regression test<sup>42</sup> were used on logit(TPR) to evaluate possible publication bias. The analysis was performed using Stata 13 (Stata Corporation, College Station, Texas, USA) and the command `mymeta` with the method of moments for multivariate meta-analysis and meta-regression<sup>43</sup>. Statistical significance was set at  $p < 0.05$ . Meta-analysis was performed in cases where two or more studies were available, whereas meta-regression and tests for publication bias when 5 or more studies were available.

## Results

The electronic search revealed 115 articles from PubMed, 72 from medRxiv and 12 from bioRxiv, from which we identified 38 eligible studies after scrutiny<sup>25-37, 44-68</sup> (Figure 1). These include in total 7,848 individuals (3,522 COVID-19 cases and 4,326 healthy, or non COVID-19, individuals). 21 studies reported data for both COVID-19 cases and controls, whereas 17 studies reported data only for COVID-19 cases. 13 studies used RT-PCR or other nucleic acid-based tests (NATs) as the gold standard for case ascertainment, whereas 25 studies ascertained COVID-19 cases using a combination of molecular and clinical features. The summary information of the included studies is presented in Table 1. We did not consider the results of different kits as separate, but we based our analysis in grouping the tests based on the method and the specific antigen used. In total we identified kits by 25 different companies, plus the various in-house tests produced for research purposes, so a separate analysis would be impossible. Several studies reported the results of multiple tests on the same individuals; however they were not included in the same meta-analysis since we analyzed each test separately. In one study that compared several different LFIA tests, we used the results of the one with the median performance (even though the differences were small). Other studies reported samples from multiple populations, and in such cases they were considered distinct.

14 studies in total reported results from ELISA-based tests (detecting anti-N or anti-S IgG, IgM antibodies or both). S-based ELISAs, in general, perform better compared to those based on N antigen. IgG and IgM seem to perform similarly, but the combination of IgG and IgM seems to be superior leading to a sensitivity of 0.935 (95% CI: 0.900, 0.971). All methods seem to have rather high specificities (ranging from 0.961 to 0.995). Meta-regression analysis showed that the mean number of days from disease onset and the proportion of severe/critical patients have an influence on the overall sensitivity of the IgG tests. Both Egger's and Begg's tests did not detect publication bias or other small study effects.

CLIA-based tests were used in 13 studies. In all cases anti-N and anti-S IgGs and IgMs were investigated. In this analysis we also pooled together the studies that considered NS antigens with the studies that used S antigen. The sensitivities of detecting IgG seem to be better compared to that of IgM (0.944 vs. 0.810). Combining IgM and IgG yields a slightly worse sensitivity (0.907, 95% CI: 0.753, 1.000) but this estimate arises from only two studies (970 patients) and thus has large uncertainty. Specificities range from 0.971 to 0.984. Meta-regression analysis revealed that the mean number of days from disease onset has an influence



on the overall outcome in the IgG tests. The Begg's test provided some evidence for publication bias in the IgG analysis.

13 studies reported results from LFIA-based tests. The majority of the tests identified antibodies against both N and S antigens and results were obtained for both IgG and IgM. In this analysis we also pooled together the studies that considered NS antigens with the studies that used S antigen. IgG and IgM seem to perform comparably, but rather low since the sensitivities range from 0.53 to 0.66. Combining IgG and IgM yields better estimates (0.78-0.83), but still with lower sensitivity compared to ELISA-based tests. Specificity in all cases ranged from 0.914 to 0.994. In the largest overall analysis, pooling together the 11 studies that used N, S, or NS antigens, the combination of IgG and IgM antibodies yields a sensitivity of 0.800 (95% CI: 0.663, 0.935) and specificity of 0.984 (95% CI: 0.969, 0.999). Meta-regression analysis revealed that the mean number of days from disease onset influences the overall outcome in the IgG and IgG/IgM tests. Both Egger's and Begg's tests could not find evidence for publication bias or other small study effects.

Lastly, FIA-based tests were found in three studies using a combination of N and S antigens. Both IgG and IgM show similar sensitivities (~0.86) and specificities (0.95), however the sample is small (3 studies, 327 patients). Due to the small number of studies, tests for publication bias or meta-regression could not be applied.

## Discussion

Non-pharmaceutical interventions including increased testing rates, contact tracing, school closures, ban of mass gatherings, physical distancing, restriction of movement, and cordon sanitaire were effective in reducing transmission rates of SARS-CoV-2 in Wuhan, China and other settings<sup>69</sup>. However, this type of intervention has tremendous societal and economic consequences potentially resulting in social disorganization and great recession. One approach to de-escalating public health measures and returning to a state of normalcy, while maintaining epidemiological vigilance and ability to respond fast to viral resurgence, is to identify people with immunity to SARS-CoV-2 and estimate their proportion in the entire population. This approach would indicate immune people including health-care workers who can go back to work without risking their health or that of others, help reopen borders, and monitor the development of herd immunity. Unfortunately, human immune response to the new pathogen is not well studied yet. The serological tests that have recently been developed employ different methods and target either IgG or IgM or both. In an attempt to fill the knowledge gap, this systematic review summarized evidence from 38 studies involving 7,848 individuals. The meta-analysis showed that all methods yielded high specificity with some of the methods (ELISA and LFIA) reaching levels higher than 99%. ELISA- and CLIA-based methods performed better in terms of sensitivity (90-96%) followed by LFIA and FIA with sensitivities ranging from 80% to 86%.

Sample quality, low antibody concentrations and especially timing of the test - too soon after a person is infected when antibodies have not been developed yet or too late when IgM antibodies have decreased or disappeared - could potentially explain the low ability of the antibody tests to identify people with COVID-19. According to kinetic measurements of some of the included studies<sup>22, 49, 54</sup> IgM peaks between days 5 and 12 and then drops slowly. IgGs reach peak concentrations after day 20 or so as IgM antibodies disappear. This meta-analysis showed, through meta-regression, that IgG tests did have better sensitivity when the samples were taken longer after the onset of symptoms. This is further corroborated by the lower specificity of IgM antibodies compared to IgG<sup>15</sup>. Only few of the included studies provided data stratified by the time of onset of symptoms, so a separate stratified analysis was not feasible, but this should be a goal for future studies. Moreover, irrespective of the method, a

combined IgG/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody type alone. The analyses also showed that tests that use the S antigen are more sensitive than N antigen-based tests probably due to higher sensitivity and earlier immune response to the S antigen<sup>52</sup> and more specific perhaps due to less cross-reactivity with less conserved regions of spike proteins existing in other coronaviruses (SARS-CoV)<sup>17, 55, 64</sup>. Combining N and S antigens further improves sensitivity. Finally, despite the suboptimal sensitivity, antibody tests could certainly supplement NATs in the diagnosis of people with suspected SARS-CoV-2 infection<sup>65</sup>. In any case, a direct comparison of antibody tests against NATs is also needed in future studies (in the current review only a handful of studies performed this, and they did that only in COVID-19 patients).

Antibody tests for SARS-CoV-2 have other accuracy issues that deserve attention and further assessment. For instance, cross-reaction with human endemic coronaviruses could make antibody tests less specific and produce false positive results<sup>30, 33, 55, 63</sup>. A low specificity may have important consequences both in terms of diagnosis and population surveillance. On the individual level, false positive results pose risks as people who have never been infected are perhaps allowed to work or travel because they are considered immune. On a population level and regarding epidemiological studies, given the low prevalence of SARS-CoV-2 in most settings at the moment, false positives may inflate prevalence estimates and give a distorted picture of lower mortality rate and higher population immunity than what is in reality. On the other hand, low sensitivity may result in falsely assuming that a person is not infected and consequently jeopardizing measures to prevent the spread of the epidemic. Based on the results of this meta-analysis, ELISA tests that achieved specificity higher than 99% and sensitivity ~93% could be the safer choice at this stage of the pandemic. CLIA tests show comparable sensitivity (~90%) but slightly decreased specificity (95-98%). LFIA tests on the other hand are particularly attractive for large seroprevalence studies and can be used as POC tests. They show high specificity, comparable to ELISA (~99%), but lower sensitivity (~80%), and these estimates should be taken into account when designing and performing seroprevalence studies, for instance, by adjusting properly the obtained positive and negative findings. On the individual level, perhaps mixed strategies could be adopted (for instance re-testing a negative finding).

Of note, even if tests are highly accurate, much about protective immunity is unknown and the true presence of binding antibodies might not mean that people have indeed developed high titers of neutralizing antibodies and are thus immune to re-infection<sup>70</sup>. Research on Rhesus macaques infected with SARS-CoV-2 was promising though showing that reinfection did not occur following rechallenge with the same dose of SARS-CoV-2 strain<sup>71</sup>. Finally, viral load does not decline rapidly after seroconversion and people may remain infectious despite being truly positive in antibodies tests<sup>35</sup>.

## Contributors


PG conceived the study, participated in data collection and performed the analysis. PK, GB, ND and GN participated in data collection and in the interpretation of the results. All authors participated in drafting the manuscript. All authors read and approved the final version of the manuscript.

## Declaration of interests

The authors declare that they have no competing interests.


## Acknowledgments

**Figure 1 Study selection**






**Figure 2 Sensitivity performance of antibody tests**



**Figure 3 Specificity performance of antibody tests**



**Table 1: Characteristics of the 38 studies included in the meta-analysis. NR: not reported**

DOI	Author	Covid19/ Healthy	Covid19 Ascertain ment	Severe Covid19 (%)	Male cases (%)	Cases Age	Days from Onset	Antibodies	Method
10.1101/2020.03.06.20031856	Liu <sup>27</sup>	238/120	NAT / clinical features	NR	58	55	14.29	IgM (N) / IgG (N)	ELISA
10.1101/2020.03.18.20038018	Long <sup>54</sup>	262/148	NAT	13.6	55.4	47	12.67	IgM (N,S) / IgG (N,S)	CLIA
10.1101/2020.02.28.20029025	Jia <sup>37</sup>	33/242	NAT / clinical features	NR	NR		15.5	IgM (N,S) / IgG (N,S)	FIA
10.1101/2020.03.26.20044883	Liu <sup>53</sup>	95/84	NAT	49	70	76	17.81	IgM (N) / IgG (N)	LFIA
10.1101/2020.03.18.20038513	Xu <sup>60</sup>	10/0	NAT	100	60		22	IgM (S) / IgG (S)	LFIA
10.1101/2020.03.22.20041285	Wang <sup>34</sup>	116/0	NAT / clinical features	12.9	56	68.8	31.6	IgM (N,S) / IgG (N,S)	CLIA
10.1101/2020.02.27.20028787	Xiang <sup>28</sup>	63/35 ELISA, 91/35 LFIA	NAT / clinical features	6.3	55.5	57.82	NR	IgM (N,S) / IgG (N,S)	ELISA / LFIA
10.1101/2020.03.17.20036954	Zhang <sup>64</sup>	154/660	NAT / clinical features	NR	NR		NR	IgM (S) / IgG (S)	LFIA
10.1101/2020.03.27.20045153	Lin <sup>33</sup>	79/80	NAT / clinical features	NR	35	43.6	13.97	IgM (N) / IgG (N)	ELISA / CLIA
10.1101/2020.03.12.20034231	Hu <sup>36</sup>	34/9	NAT	NR	NR		NR	IgM (N,S) / IgG (N,S)	FIA
10.1101/2020.03.12.20035048	Zhang <sup>32</sup>	222/0	NAT	39.2	48.2	64	19.5	IgM (N,S) / IgG (N,S)	CLIA
10.3201/eid2607.200841	Okba <sup>55</sup>	12/0	NAT	NR	NR		11	IgG (S)	ELISA
10.1101/2020.03.04.20030916	Zhang <sup>63</sup>	3/733	NAT / clinical features	66.6	66.6	50.67	10	IgM (N,S) / IgG (N,S)	CLIA
10.1101/2020.03.26.20042184	Zhao <sup>66</sup>	69/412	NAT / clinical features	NR	NR		NR	IgM (S) / IgG (S)	ELISA

10.1101/2020.03.13.20035428	Pan <sup>56</sup>	86/0	NAT / clinical features	NR	45.7	58	12.05	IgM (N,S) / IgG (N,S)	LFIA
10.1101/2020.03.23.20041707	Lou <sup>31</sup>	80/300	NAT / clinical features	33	61.3	55	15	IgM (N,S) / IgG (N,S)	ELISA / CLIA / FLIA
10.1101/2020.03.28.20045765	Liu <sup>27</sup>	133/0	NAT / clinical features	66.9	52.6	68.5	NR	IgM (N,S) / IgG (N,S)	CLIA
10.1101/2020.03.24.20042382	Tan <sup>58</sup>	65/0	NAT / clinical features	43.3	52.2	49	15.4	IgM (N) / IgG (N)	ELISA
10.1016/S1473-3099(20)30196-1	To <sup>59</sup>	16/0	NAT / clinical features	43.5	56.5	62	20	IgM (N,S) / IgG (N,S)	ELISA
10.1016/j.jinf.2020.03.012	Xiao <sup>29</sup>	34/0	NAT / clinical features	NR	64.7	55	25.5	IgM (N,S) / IgG (N,S)	CLIA
10.1002/jmv.25800	Cassaniti <sup>46</sup>	30/38	NAT	NR	83.3	73.5/61.5	7	IgM (N,S) / IgG (N,S)	LFIA
10.1128/JCM.00461-20	Liu <sup>52</sup>	214/100	NAT	NR	NR		15	IgM (N,S) / IgG (N,S)	ELISA
10.1002/jmv.25727	Li <sup>26</sup>	397/128	NAT	NR	NR		20	IgM (S) / IgG (S)	LFIA
10.1093/cid/ciaa344	Zhao <sup>65</sup>	173/0	NAT / clinical features	18.5	48.5	48	7	IgM (S) / IgG (S)	ELISA
10.3760/cma.j.isn.0253-9624.2020.0005	Bai <sup>44</sup>	6/0	NAT / clinical features	16.7	50	49	2	IgM (N,S)	LFIA
10.1016/j.ijid.2020.03.047	Zheng <sup>67</sup>	55/0	NAT / clinical features	40	43.6	60	11	IgM (N,S) / IgG (N,S)	CLIA
10.1001/jama.2020.4861	Zeng <sup>61</sup>	6/0	NAT / clinical features	0	0		NR	IgM (N,S) / IgG (N,S)	CLIA
10.1093/cid/ciaa310	Guo <sup>49</sup>	140/285	NAT / clinical features	23.6	NR		13.21	IgM (N)	ELISA
10.1016/j.ijid.2020.03.065	Jin <sup>50</sup>	27/33	NAT	0	39.5	47	16	IgM (N,S) / IgG (N,S)	CLIA

10.1002/jmv.25820	Du <sup>25</sup>	60/0	NAT / clinical features	NR	NR		43.47	IgM (N,S) / IgG (N,S)	CLIA
10.1038/s41586-020-2196-x	Wölfel <sup>35</sup>	9/0	NAT / clinical features	0	NR		17.8	IgM (S) / IgG (S)	IFA
10.1007/s11427-020-1688-9	Zhong <sup>68</sup>	47/300	NAT	23.4	34	48.21	15.47	IgM (N,S) / IgG (N,S)	ELISA / CLIA
10.1101/2020.04.09.20056325	Lassaunière <sup>30</sup>	30/82	NAT	100	NR		NR	IgM (N,S) / IgG (N,S)	ELISA / LFIA
10.1101/2020.03.26.20042044	Gao <sup>47</sup>	38/0	NAT / clinical features	7.9	55.3	40.5	15.8	IgM (N,S) / IgG (N,S)	LFIA
10.1016/j.jinf.2020.03.052	Zeng <sup>62</sup>	27/36	NAT / clinical features	63	51.8	62	18	IgM (N) / IgG (N)	ELISA
10.1101/2020.04.11.20062158	Garcia <sup>48</sup>	118/45	NAT / clinical features	NR	67.8	65.14	14.2	IgM (N,S) / IgG (N,S)	LFIA
10.1101/2020.04.03.20052183	Paradiso <sup>57</sup>	191/0	NAT / clinical features	NR	60.62	58.5	4.12	IgM (N,S) / IgG (N,S)	LFIA
10.1101/2020.04.14.20062463	Bendavid <sup>45</sup>	122/456	NAT	NR	NR	NR	NR	IgM (N,S) / IgG (N,S)	LFIA

**Table 2. Results of the meta-analysis for the different types of antibody tests. We list the characteristics of the included studies, the pooled sensitivity and specificity along with the 95% confidence intervals, the variables that were found statistically significant in meta-regression and the results of the tests for publication bias. For the description of the test, the antibodies (ab) and antigens (ag), see Methods section (mdfo: mean days from onset; severe: percent of patients with severe or critical condition; NA: not applicable)**

Method	Ab	Ag	Studies/ Patients	Sensitivity (95% CI)	Specificity (95% CI)	covariates	Begg's/ Egger's
ELISA	IgG	N	8/1472	0.747 (0.509, 0.984)	0.994 (0.988, 0.999)	mdfo, severe	-/-
ELISA	IgG	S	7/1072	0.814 (0.688, 0.940)	0.961 (0.910, 1.000)	-	-/-
ELISA	IgM	N	8/1717	0.722 (0.449, 0.996)	0.995 (0.989, 1.000)	-	-/-
ELISA	IgM	S	6/1328	0.817 (0.704, 0.931)	0.991 (0.976, 1.000)	-	-/-
ELISA	IgG/IgM	N	2/423	0.808 (0.764, 0.853)	0.967 (0.915, 0.987)	NA	NA
ELISA	IgG/IgM	S	5/1244	0.935 (0.900, 0.971)	0.987 (0.973, 1.000)	-	-/-
LFIA	IgG	S	2/535	0.537 (0.123, 0.951)	0.914 (0.853, 0.951)	NA	NA
LFIA	IgG	NS	8/944	0.650 (0.404, 0.895)	0.988 (0.973, 1.000)	mdfo	-/-
LFIA	IgG	S/NS	10/1479	0.626 (0.439, 0.814)	0.964 (0.922, 1.000)	-	-/-
LFIA	IgM	S	2/535	0.663 (0.236, 1.000)	0.914 (0.852, 0.951)	NA	NA
LFIA	IgM	NS	9/1059	0.528 (0.329, 0.726)	0.986 (0.974, 0.998)	-	-/-
LFIA	IgM	S/NS	11/1594	0.555 (0.352, 0.758)	0.979 (0.958, 0.999)	-	-/-
LFIA	IgG/IgM	S	2/824	0.828 (0.770, 0.886)	0.994 (0.984, 0.998)	NA	NA
LFIA	IgG/IgM	NS	8/1373	0.777 (0.592, 0.962)	0.986 (0.973, 1.000)	mdfo	-/-
LFIA	IgG/IgM	S/NS	10/2197	0.793 (0.643, 0.942)	0.989 (0.978, 0.999)	mdfo	-/-
LFIA	IgG/IgM	S/N/N S	11/2376	0.800 (0.663, 0.935)	0.984 (0.969, 0.999)	mdfo	-/-
CLIA	IgG	NS	12/2320	0.944 (0.906, 0.983)	0.971 (0.931, 1.000)	mdfo	-/+
CLIA	IgG	N/NS	13/2479	0.935 (0.896, 0.975)	0.974 (0.953, 0.994)	mdfo	-/+
CLIA	IgM	NS	12/2411	0.810 (0.722, 0.897)	0.984 (0.970, 0.999)	-	-/-
CLIA	IgM	N/NS	13/2570	0.799 (0.737, 0.860)	0.967 (0.927, 1.000)	-	-/-
CLIA	IgG/IgM	NS	2/790	0.907 (0.753, 1.000)	0.981 (0.944, 1.000)	NA	NA
CLIA	IgG/IgM	N/NS	3/949	0.902 (0.811, 0.993)	0.954 (0.875, 1.000)	NA	NA
FIA	IgG	NS	2/ 318	0.859 (0.339, 1.000)	0.950 (0.923, 0.977)	NA	NA

FIA	IgG	S/NS	3/327	0.890 (0.591, 1.000)	0.950 (0.923, 0.977)	NA	NA
FIA	IgM	NS	2/ 318	0.860 (0.500, 1.000)	0.950 (0.923, 0.977)	NA	NA
FIA	IgM	S/NS	3/327	0.786 (0.531, 1.000)	0.950 (0.923, 0.977)	NA	NA

## References

1. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*. 2020;395(10223):514-23.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020;579(7798):265-9.
3. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *International journal of surgery (London, England)*. 2020;76:71-6.
4. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *Journal of medical virology*. 2020;92(5):491-4.
5. Promislow DEL. A geroscience perspective on COVID-19 mortality. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2020.
6. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging*. 2020;12(7):6049-57.
7. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020.
8. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell host & microbe*. 2020;27(3):325-8.
9. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nature reviews Microbiology*. 2019;17(3):181-92.
10. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet (London, England)*. 2020;395(10224):565-74.



11. Woo PC, Lau SK, Wong BH, Tsoi HW, Fung AM, Kao RY, et al. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. *Journal of clinical microbiology*. 2005;43(7):3054-8.
12. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
13. Chang CK, Sue SC, Yu TH, Hsieh CM, Tsai CK, Chiang YC, et al. Modular organization of SARS coronavirus nucleocapsid protein. *Journal of biomedical science*. 2006;13(1):59-72.
14. Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. *Journal of virology*. 2009;83(14):7221-34.
15. Tang YW, Schmitz JE, Persing DH, Stratton CW. The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges. *Journal of clinical microbiology*. 2020.
16. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veers D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020;181(2):281-92.e6.
17. Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. *Cellular & molecular immunology*. 2020.
18. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(3).
19. ECDC. European Centre for Disease Prevention and Control, Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK - sixth update-12 March 2020. Stockholm: 2020.
20. Service RF. The standard coronavirus test, if available, works well—but can new diagnostics help in this pandemic? *ScienceMag*. 2020.
21. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *The New England journal of medicine*. 2020;382(10):929-36.
22. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. *Journal of clinical medicine*. 2020;9(3).
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*. 2009;6(7):e1000097.
24. Forero DA, Lopez-Leon S, González-Giraldo Y, Bagos PG. Ten simple rules for carrying out and writing meta-analyses. *PLoS Comput Biol*. 2019;15(5):e1006922-e.
25. Du Z, Zhu F, Guo F, Yang B, Wang T. Detection of antibodies against SARS-CoV-2 in patients with COVID-19. *Journal of medical virology*. 2020.
26. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *Journal of medical virology*. 2020.
27. Liu R, Liu X, Han H, Shereen MA, Niu Z, Li D, et al. The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis. *medRxiv*. 2020:2020.03.28.20045765.
28. Xiang J, Yan M, Li H, Liu T, Lin C, Huang S, et al. Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of

- Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19). medRxiv. 2020:2020.02.27.20028787.
29. Xiao DAT, Gao DC, Zhang DS. Profile of Specific Antibodies to SARS-CoV-2: The First Report. *The Journal of infection*. 2020.
30. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt KA, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020:2020.04.09.20056325.
31. Lou B, Li T, Zheng S, Su Y, Li Z, Liu W, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv. 2020:2020.03.23.20041707.
32. Zhang B, Zhou X, Zhu C, Feng F, Qiu Y, Feng J, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv. 2020:2020.03.12.20035048.
33. Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al. Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak. medRxiv. 2020:2020.03.27.20045153.
34. Wang Z, Li H, Li J, Yang C, Guo X, Hu Z, et al. Elevated serum IgM levels indicate poor outcome in patients with coronavirus disease 2019 pneumonia: A retrospective case-control study. medRxiv. 2020:2020.03.22.20041285.
35. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020.
36. Hu X, An T, Situ B, Hu Y, Ou Z, Li Q, et al. Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2. medRxiv. 2020:2020.03.12.20034231.
37. Jia X, Zhang P, Tian Y, Wang J, Zeng H, Wang J, et al. Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection. medRxiv. 2020:2020.02.28.20029025.
38. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. *Statistics in Medicine*. 1993;12(24):2273-84.
39. Arends LR, Hamza TH, van Houwelingen JC, Heijenbrok-Kal MH, Hunink MG, Stijnen T. Bivariate random effects meta-analysis of ROC curves. *Medical decision making : an international journal of the Society for Medical Decision Making*. 2008;28(5):621-38.
40. Liu Y, Chen Y, Chu H. A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard. *Biometrics*. 2015;71(2):538-47.
41. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50(4):1088-101.
42. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629.
43. White IR. Multivariate random-effects meta-regression: Updates to mvmeta. *Stata Journal*. 2011;11(2):255-70.
44. Bai SL, Wang JY, Zhou YQ, Yu DS, Gao XM, Li LL, et al. [Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province]. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2020;54(0):E005.
45. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. medRxiv. 2020:2020.04.14.20062463.
46. Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, et al. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. *Journal of medical virology*. 2020.

47. Gao Y, Yuan Y, Li TT, Wang WX, Li YX, Li A, et al. Evaluation the auxiliary diagnosis value of antibodies assays for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19). medRxiv. 2020:2020.03.26.20042044.
48. Garcia FP, Perez Tanoira R, Romanyk Cabrera JP, Arroyo Serrano T, Gomez Herruz P, Cuadros Gonzalez J. Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies with an immunochromatographic device: a prospective single-center study. medRxiv. 2020:2020.04.11.20062158.
49. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
50. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;94:49-52.
51. Liu L, Liu W, Wang S, Zheng S. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv. 2020:2020.03.06.20031856.
52. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. Journal of clinical microbiology. 2020:JCM.00461-20.
53. Liu Y, Liu Y, Diao B, Ren F, Wang Y, Ding J, et al. Diagnostic Indexes of a Rapid IgG/IgM Combined Antibody Test for SARS-CoV-2. medRxiv. 2020:2020.03.26.20044883.
54. Long Q-x, Deng H-j, Chen J, Hu J, Liu B-z, Liao P, et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv. 2020:2020.03.18.20038018.
55. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerging infectious diseases. 2020;26(7).
56. Pan Y, Li X, Yang G, Fan J, Tang Y, Zhao J, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. Journal of Infection. 2020.
57. Paradiso AV, De Summa S, Loconsole D, Procacci V, Sallustio A, Centrone F, et al. Clinical meanings of rapid serological assay in patients tested for SARS-Co2 RT-PCR. medRxiv. 2020:2020.04.03.20052183.
58. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv. 2020:2020.03.24.20042382.
59. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious diseases. 2020.
60. Xu Y. Dynamic profile of severe or critical COVID-19 cases. medRxiv. 2020:2020.03.18.20038513.
61. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. Jama. 2020.
62. Zeng Z, Chen L, Pan Y, Deng Q, Ye G, Li Y, et al. Re: Profile of specific antibodies to SARS-CoV-2: The first report. The Journal of infection. 2020.
63. Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. medRxiv. 2020:2020.03.04.20030916.

64. Zhang P, Gao Q, Wang T, Ke Y, Mo F, Jia R, et al. Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19). medRxiv. 2020:2020.03.17.20036954.
65. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
66. Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, et al. Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins. medRxiv. 2020:2020.03.26.20042184.
67. Zheng C, Wang J, Guo H, Lu Z, Ma Y, Zhu Y, et al. Risk-adapted Treatment Strategy For COVID-19 Patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
68. Zhong L, Chuan J, Gong BO, Shuai P, Zhou Y, Zhang Y, et al. Detection of serum IgM and IgG for COVID-19 diagnosis. Science China Life sciences. 2020.
69. Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. Jama. 2020.
70. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020:2020.03.30.20047365.
71. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020:2020.03.13.990226.